Emerging Insights in Mantle Cell Lymphoma From ASH 2025

home / post-conference-perspectives / emerging-insights-in-mantle-cell-lymphoma-from-ash-2025

Michael Wang, MD, endowed professor in the department of Lymphoma & Myeloma at MD Anderson at MD Anderson Cancer Center in Houston, Texas, discusses data in mantle cell lymphoma presented at ASH 2025.

EP. 1: Sonrotoclax Shows Promising Efficacy, Improved Tolerability in Heavily Pretreated MCL

Michael Wang, MD

December 23rd 2025

At ASH 2025, sonrotoclax demonstrated encouraging response rates and a favorable safety profile as a single-agent BCL2 inhibitor in heavily pretreated, largely refractory mantle cell lymphoma.

Watch

EP. 2: Duration of Response With Sonrotoclax Vs Current Therapies for MCL

Michael Wang, MD

December 23rd 2025

At ASH 2025, sonrotoclax demonstrated encouraging response rates and a favorable safety profile as a single-agent BCL2 inhibitor in heavily pretreated, largely refractory mantle cell lymphoma.

Watch

EP. 3: Ushering in a New Combination-Driven Era in MCL

Michael Wang, MD

January 8th 2026

Early ASH 2025 data suggest sonrotoclax is a promising therapy in MCL, supporting a broader shift toward chemo-free, combination-based strategies—particularly for patients with BTK inhibitor–refractory disease.

Watch

EP. 4: ASH 2025 Highlights Reinforce Durability, Safety, and Strategic Sequencing in MCL Therapy

Michael Wang, MD

January 8th 2026

Michael Wang, MD, reviews ASH 2025 data showing durable safety with long-term BTK inhibition, promising next-generation targeted agents, sustained CAR T-cell efficacy, and evidence favoring upfront combination therapy over sequential treatment in mantle cell lymphoma.

Watch